Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557057 · ClinicalTrials.gov registry record
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
A clinical trial of HER2-Positive Breast Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 66
- Enrollment target
- 1
- Study location
NCT06557057 is a study of HER2-Positive Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 66 participants, below the 162-participant average among 12 other HER2-Positive Breast Carcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06557057, a study of HER2-Positive Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06557057
The ClinicalTrials.gov registry entry for NCT06557057 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 12 other HER2-Positive Breast Carcinoma trials with a reported enrollment target (59% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-Positive Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06557057 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06557057 about?
NCT06557057 is a clinical study titled "Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk". This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
What is the current status of trial NCT06557057?
This trial is currently recruiting. The enrollment target is 66 participants. The study started on 2023-11-16. Estimated completion is 2026-12-01.
What conditions does trial NCT06557057 study?
This clinical trial studies the following conditions: HER2-Positive Breast Carcinoma.
What interventions are being tested in trial NCT06557057?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06557057?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06557057 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Positive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
RECRUITING
-
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
RECRUITING · Phase 2
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.